TD Cowen on Mirum Pharmaceuticals (MIRM): 'We continue to view shares as undervalued'

October 12, 2026 9:36 AM EDT Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating and $140.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login